Skip to content
value.today

Beta Bionics, Inc

Total raised
$277 M
4 rounds on record
Latest round
$100 M
Aug 2023
First round on record
Dec 2017
Today
Went public
See the company page

Beta Bionics, Inc is listed today as Beta Bionics, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Beta Bionics, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$100 MNo. 4$50 to $250 million

Beta Bionics, Inc: Raise no. 4, Aug 2023

Investors in this round

29 investors had bought by the notice of Sep 15, 2023: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Beta Bionics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $102 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Edward Damiano · Executive Officer, Director · Executive Chairman
  • Sean T. Saint · Executive Officer, Director · Chief Executive Officer
  • Stephen H. Feider · Executive Officer · Chief Financial Officer, Secretary
  • Amanda T. Black · Director
  • Francesco T. Draetta · Director
  • Gilad T. Glick · Director
  • Lennox T. Ketner · Director
  • Parker T. Cassidy · Director
  • Sean D. Carney · Director
  • Westley T. Dupray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean T. Saint, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2023. Read the notice at the SEC.

equity, optionsSEC
Feb 2022$57 MNo. 3$50 to $250 million

Beta Bionics, Inc: Raise no. 3, Feb 2022

Investors in this round

21 investors had bought by the notice of Mar 2, 2022: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Beta Bionics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$57 M of $57 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Gibb Clarke · Executive Officer · Chief Financial Officer
  • Marcie Cain · Executive Officer · Chief People Officer
  • Martha Aronson · Executive Officer, Director · Interim Chief Executive Officer
  • Michael Pereira · Executive Officer · Chief Operating Officer
  • Veena Rao · Executive Officer · Chief Commercial Officer
  • Beth Brooke · Director
  • Christy Jones · Director
  • Edward Damiano · Director
  • Finny Kuruvilla · Director
  • Jeff Hitchcock · Director
  • Sean Carney · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gibb Clarke, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 2, 2022. Read the notice at the SEC.

equity, optionsSEC
Jul 2019$63 MNo. 2$50 to $250 million

Beta Bionics, Inc: Raise no. 2, Jul 2019

Investors in this round

12 investors had bought by the notice of Jul 22, 2019: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Beta Bionics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$63 M of $63 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Edward Damiano · Executive Officer, Director
  • Edward Raskin · Executive Officer, Director
  • Gilbert Clarke · Executive Officer
  • Mike Roskino · Executive Officer
  • Serafina Raskin · Executive Officer
  • Adam Steensberg · Director
  • Agustin Mohedas · Director
  • Jeff Hitchcock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Serafina Raskin, VP, General Counsel. Source: SEC Form D, newest notice filed Jul 22, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$58 MNo. 1$50 to $250 million

Beta Bionics, Inc: Raise no. 1, Dec 2017

Investors in this round

24 investors had bought by the notice of Oct 23, 2018: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Beta Bionics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$58 M (amount offered: indefinite)
Smallest investment taken
$1
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$825,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Edward B. Raskin · Executive Officer, Director
  • Edward R. Damiano · Executive Officer, Director
  • Gilbert H Clarke · Executive Officer
  • Mike H Rosinko · Executive Officer
  • Serafina H Raskin · Executive Officer
  • Thomas A. Fitzgerald · Executive Officer
  • CHRISTIAN H Foged · Director
  • Deirdre B. Ibsen · Director
  • Jeffrey B. Hitchcock · Director
  • Martin H Lange · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · Minneapolis, MinnesotaSold in CO, DE, MA, NE, NY, and outside the US

Signed by Serafina Raskin, VP, General Counsel. Source: SEC Form D and 2 amendments, newest notice filed Oct 23, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Beta Bionics, Inc., its revenue in fiscal 2025 came from these product and service lines: iLet $52.75 million (53%), Single-use Products $47.50 million (47%).

    Annual report (SEC XBRL) · Dec 2025

  • Beta Bionics, Inc chose not to state its revenue in its newest notice of a funding round (Sep 2023).

    SEC Form D · Sep 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2023

Products and services#

No products or services of Beta Bionics, Inc are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Beta Bionics, Inc
InvestorKindAmountRoundRoleSource
Mike MensingerPersonnot statednot statedHeld Series D preferred stock (Form 3, 2025)SEC Form 3
Wellington Hadley Harbor Aggregator IV, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 29 investors.

Largest shareholders today

Institutions holding Beta Bionics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Beta Bionics, Inc
NameRoleNamed in
Edward DamianoExecutive ChairmanSep 2023
Sean T. SaintChief Executive OfficerSep 2023
Stephen H. FeiderChief Financial Officer, SecretarySep 2023
Gibb ClarkeChief Financial OfficerMar 2022
Marcie CainChief People OfficerMar 2022
Martha AronsonInterim Chief Executive OfficerMar 2022
Michael PereiraChief Operating OfficerMar 2022
Veena RaoChief Commercial OfficerMar 2022
Edward RaskinExecutive officerJul 2019
Gilbert ClarkeExecutive officerJul 2019
Mike RoskinoExecutive officerJul 2019
Serafina RaskinExecutive officerJul 2019
Edward B. RaskinExecutive officerOct 2018
Edward R. DamianoExecutive officerOct 2018
Gilbert H ClarkeExecutive officerOct 2018
Mike H RosinkoExecutive officerOct 2018
Serafina H RaskinExecutive officerOct 2018
Thomas A. FitzgeraldExecutive officerOct 2018
Amanda T. BlackDirectorSep 2023
Edward DamianoExecutive ChairmanSep 2023
Francesco T. DraettaDirectorSep 2023
Gilad T. GlickDirectorSep 2023
Lennox T. KetnerDirectorSep 2023
Parker T. CassidyDirectorSep 2023
Sean D. CarneyDirectorSep 2023
Sean T. SaintChief Executive OfficerSep 2023
Westley T. DuprayDirectorSep 2023
Beth BrookeDirectorMar 2022
Christy JonesDirectorMar 2022
Finny KuruvillaDirectorMar 2022
Jeff HitchcockDirectorMar 2022
Martha AronsonInterim Chief Executive OfficerMar 2022
Sean CarneyDirectorMar 2022
Adam SteensbergDirectorJul 2019
Agustin MohedasDirectorJul 2019
Edward RaskinDirectorJul 2019
CHRISTIAN H FogedDirectorOct 2018
Deirdre B. IbsenDirectorOct 2018
Edward B. RaskinDirectorOct 2018
Edward R. DamianoDirectorOct 2018

Went public since 2025. Its SEC number is that of a company listed on a stock exchange.